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Open access uTo close the stable door before the horse has boltedTo the Editor:
We read with interest the studies by Fagundes and colleagues [1],
Piano and colleagues [2] and the accompanying editorial [3].
Both studies evaluated large numbers of patients with cirrhosis
(375 and 233, respectively) and assessed the impact of acute kidney
injury (AKI), assessedbothbyAKIN criteria and themore conventional
ﬁnding of a creatinine level ofP1.5 mg/dl. Piano and colleagues only
included patients with hospital acquired AKI, thus excluding patients
who already had renal impairment on admission. In this study, all
patients had ascites, while in the study by Fagundes and colleagues
this was present in two thirds. In both studies, patients with stage 1
AKI with a peak creatinine <1.5 mg/dl did not have an increasedmor-
tality as compared to patients without AKI. The accompanying edito-
rial therefore suggests the conclusion that stage 1 AKI with a peak
creatinine of <1.5 mg/dl is a benign condition.
The importance of renal failure in cirrhosis is well established.
It increases the risk of dying 7-fold and carries a 1 month mortal-
ity of up to 50% [4], an impact on the natural history of a magni-
tude similar to that of bacterial infections [5]. Creatinine as an
indicator of renal function is an essential component of prognos-
tic scores such as MELD and UKELD. Both the stage of AKI and the
peak creatinine level are associated with increased mortality [6].
Tsien and colleagues [7] recently published a prospective study
on 90 outpatients with cirrhosis and ascites. Episodes of AKI (as
per AKIN criteria) were common, and the mean peak creatinine
value was within normal laboratory values. Importantly, patients
with an episode of AKI had decreased survival on follow up.
While widely used, creatinine remains an imperfect marker of
renal function in cirrhosis. Not only can high levels of bilirubin inter-
fere with creatinine measurements, but levels also correlate withJournal of Hepatology 20
nder CC BY-NC-ND license.total musclemass, which is oftenmarkedly reduced in patients with
cirrhosis and ascites [8]. As a consequence, baseline creatinine levels
in patients with cirrhosis are frequently substantially lower than the
upper limit of normal used by laboratories, and substantial increases
in creatinine levelmay not exceed the ‘‘normal values’’ andmay thus
not be spotted by the non-hepatologist.
We would therefore like to disagree with the conclusion that
stage 1 AKI with a peak creatinine of <1.5 mg/dl is a ‘‘benign’’
condition. Both Fagundes’ and Piano’s study had standard inter-
ventions for patients whose creatinine increased (even if below
1.5 mg/dl), and these measures were implemented rapidly since
all patients were in hospital. These included such crucial mea-
sures as withdrawal of diuretics and nephrotoxic drugs, diagnosis
and treatment of bacterial infections and ﬂuid challenges with
crystalloids or albumin. In Tien’s study, blood tests were taken
every 4–6 weeks but clinical evaluation for assessment of AKI
only occurred every 4 months – this raises the question whether
interventions in patients with increasing renal markers were not
carried out in a similarly timely fashion. This is in line with a
recently published trial reporting improved survival in patients
with cirrhosis and ascites who were allocated to closely moni-
tored outpatient management under the care of a specialised
clinical team at a dedicated Hepatology centre [9].
In our opinion, the correct conclusion from the current evi-
dence should be that stage 1 AKI with a peak creatinine of
<1.5 mg/dl in patients with cirrhosis is a potentially benign con-
dition if promptly treated and correctly managed. If ignored and
untreated, it is likely to progress to higher stages of AKI and carry
an increased mortality. Our vigilance should therefore be aimed
at the timely detection of renal impairment in patients with14 vol. 60 j 676–683
cirrhosis and ascites, in order to intervene early and prevent
further deterioration to a point where resolution becomes less
certain and prognosis adverse.
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Reply to: ‘‘To close the stable door before the horse has bolted’’
To the Editor:
We read with great interest the letter by Thalheimer and
Burroughs in relation to our study and that of Piano et al. [1,2]
recently published in Journal of Hepatology. We appreciate their
interesting and stimulating comments as they contribute to
scientiﬁc interaction on a very important topic. We absolutely
agree with their comment that the results of our study should
be interpreted in the perspective that patients were hospitalized
in a Liver Unit and complications of cirrhosis were managed
according to international guidelines [3]. Having said that, one
of the main messages of our study is that in cirrhosis AKI stage
1 group is constituted by a heterogeneous population with
respect to prognosis, and that two very different subsets of
patients can be easily identiﬁed according to peak serum creati-
nine reached during the AKI episode. A ﬁrst subgroup, AKI stage
1a with a peak serum creatinine 61.5 mg/dl, that has a 3-month
survival close to that of patients without AKI, and a second sub-
group, AKI stage 1b, with a peak serum creatinine >1.5 mg/dl.
Patients from this latter group have a much worse prognosis,
which is intermediate between those of patients without AKI
and patients with stage 2 AKI. In our study, it is not stated that
AKI stage 1a is a benign condition. A simple look at Fig. 3 (graph
A) of the study by Fagundes et al. [1] shows that 3-month prob-
ability of survival in the group of patients with AKI stage 1a is
of 84%, which is not really a prognosis of a ‘‘benign’’ condition.
The incorporation of a maximum level of serum creatinine
reached (such as the 1.5 mg/dl used in our study) to the AKI cri-
teria makes pathophysiological sense because it adds a threshold
to deﬁne kidney dysfunction. As an example, let’s imagine two
patients with baseline serum creatinine of 0.5 mg/dl and
1.3 mg/dl respectively, who develop AKI stage 1 based on an
increase of 0.3 mg/dl in both cases. While in the former a peak
of serum creatinine of 0.8 mg/dl indicates that glomerular ﬁltra-
tion rate is still normal, in the latter a peak of 1.6 mg/dl indicates
impaired organ function (markedly reduced glomerular ﬁltra-
tion). At these levels of glomerular ﬁltration rate, the minimum
GFR reached (which corresponds to the peak serum creatinine)
has more prognostic information than a relative increase of
0.3 mg/dl. This statement is not opinion-based, it is based on data
from two different prospective studies that included a large
number of patients.
In summary, the studies by Piano et al. and Fagundes et al.
[1,2] convincingly demonstrate, in 2 independent series of
patients, that the incorporation of a peak serum creatinine of
1.5 mg/dl in stage 1 of the AKIN criteria provides very useful clin-
ical information in cirrhosis as it allows stratifying these patients
into two different subgroups with markedly different prognosis.
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